{"id":296007,"date":"2026-06-19T00:00:00","date_gmt":"2026-06-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?post_type=report&#038;p=296007"},"modified":"2026-06-20T11:11:38","modified_gmt":"2026-06-20T11:11:38","slug":"cutrim0016-2026-biopharma-ulcerative-colitis-current-treatment-current-treatment-physician-insights-ulcerative","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0016-2026-biopharma-ulcerative-colitis-current-treatment-current-treatment-physician-insights-ulcerative\/","title":{"rendered":"Ulcerative Colitis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights \u2013 Ulcerative Colitis (EU5)"},"content":{"rendered":"<p>Many well-established therapies are available to treat ulcerative colitis (<abbr title=\"ulcerative colitis\">UC<\/abbr>) in the <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>. <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha (J&#038;J Innovative Medicine\u2019s Remicade and AbbVie\u2019s Humira), a <abbr title=\"cell adhesion molecule\">CAM<\/abbr> inhibitor (Takeda\u2019s Entyvio), and an <abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor (J&#038;J Innovative Medicine\u2019s Stelara) are the most widely used biologics for moderate to severe <abbr title=\"ulcerative colitis\">UC<\/abbr> and are entrenched as first-line biologics, followed by oral targeted therapies such as <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitors (Pfizer\u2019s Xeljanz, Alfasigma\u2019s Jyseleca, and AbbVie\u2019s Rinvoq). In addition, several new therapies, including <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-23 inhibitors (Eli Lilly\u2019s Omvoh, AbbVie\u2019s Skyrizi, and J&#038;J Innovative Medicine\u2019s Tremfya), <abbr data-abbreviation-entity=\"5310\" title=\"sphingosine 1-phosphate\">S1P<\/abbr>-R modulators (<abbr data-abbreviation-entity=\"5794\" title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Zeposia and Pfizer\u2019s Velsipity), and biosimilars of infliximab, adalimumab, and ustekinumab, have been approved for <abbr title=\"ulcerative colitis\">UC<\/abbr> in Europe in the past few years. The availability of agents from different drug classes and the launch of biosimilars will not only expand treatment options but also influence physicians\u2019 prescribing behavior and thus the treatment landscape.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which drug classes are the patient-share leaders in each line of therapy? How are the various biological agents positioned in surveyed physicians\u2019 <abbr title=\"ulcerative colitis\">UC<\/abbr> treatment algorithm?<\/li>\n<li>What are the most influential drivers of treatment selection, and under which scenarios do\/will physicians prescribe Velsipity and Rinvoq?<\/li>\n<li>What are the common treatment scenarios before initiating each targeted therapy (i.e., Remicade, Humira, Simponi, Stelara, Entyvio, Omvoh, Skyrizi, Tremfya, Rinvoq, Xeljanz, Jyseleca, Zeposia, Velsipity, biosimilar infliximab, biosimilar adalimumab, and biosimilar ustekinumab)?<\/li>\n<li>What factors drive therapy discontinuation and switching? What factors have\/will drive recent\/anticipated prescribing changes?<\/li>\n<\/ul>\n<p><b>Geography<\/b><strong>: <\/strong>France, Germany, Italy, Spain, and United Kingdom<\/p>\n<p><strong>Primary research:<\/strong> 250 gastroenterologists completed the survey. Of these physicians, 50 were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded <a>in March 2026.<\/a><\/p>\n<p><strong>Key companies: <\/strong>Johnson &#038; Johnson Innovative Medicine, AbbVie, Takeda, Eli Lilly, Pfizer, <a>other<\/a>s<\/p>\n<p><strong>Key drugs: <\/strong>Humira, Remicade, Entyvio, Stelara, Omvoh, Skyrizi, Tremfya, Xeljanz, Rinvoq, Zeposia, and Velsipity<\/p>\n<p><strong>Product Description: <\/strong>Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand&#8217;s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296007","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastrointestinal","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-current-treatment","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}